Oncogenic seRNA functional activation: a novel mechanism of tumorigenesis

Yuan Tan, Yuejin Li and Faqing Tang *

Abstract

seRNA is a noncoding RNA (ncRNA) transcribed from active super-enhancer (SE), through which SE exerts biological functions and participates in various physiological and pathological processes. seRNA recruits cofactor, RNA polymerase II and mediator to constitute and stabilize chromatin loop SE and promoter region, which regulates target genes transcription. In tumorigenesis, DNA insertion, deletion, translocation, focal amplification and carcinogen factor mediate oncogenic SE generation, meanwhile, oncogenic SE transcribes into tumor-related seRNA, termed as oncogenic seRNA. Oncogenic seRNA participates in tumorigenesis through activating various signal-pathways. The recent reports showed that oncogenic seRNA implicates in a widespread range of cytopathological processes in cancer progression including cell proliferation, apoptosis, autophagy, epithelial-mesenchymal transition, extracellular matrix stiffness and angiogenesis. In this article, we comprehensively summarized seRNA’s characteristics and functions, and emphatically introduced inducible formation of oncogenic seRNA and its functional mechanisms. Lastly, some research strategies on oncogenic seRNA were introduced, and the perspectives on cancer therapy that targets oncogenic seRNA were also discussed.

Keywords: Super-enhancer, seRNA, Molecular mechanisms, Cancer progress

Background

Typical enhancer is a class of regulatory DNA sequences, its specific functional states are distinguished by a series of histone modifications characteristics [1, 2]. Super enhancer (SE) is enriched with large clusters of enhancers. SE was primarily isolated via the Rank Ordering of SE (ROSE) algorithm in murine embryonic stem cells (ESCs) in 2013 [3, 4]. It is strongly occupied with aberrant high levels of master transcription factors (TFs) (Oct4, Sox2 and Nanog), active histone marks [histone H3 lysine 4 monomethylation (H3K4me1), histone H3 lysine 27 acetylation (H3K27ac)], and transcription regulator factors (cyclin-dependent kinases (CDK)7, Mediator (MED)1, bromodomain-containing protein 4 (BRD4), polymerase II (Pol II) and p300) [5, 6]. Currently, SE identification is mainly dependent on chromatin immunoprecipitation followed by sequence analysis (CHIP-seq) [7, 8].

Classic enhancer not only regulates the transcription of target genes but also actively transcribes into enhancer RNA (eRNA). Consistently, SE also transcribes into ncRNA termed as super enhancer RNA (seRNA) [9], comprising circular RNA (circRNA), long noncoding RNA (lncRNA) and microRNA (miRNA), which play a significant role in gene expression, splicing, translation, and epigenetic regulation [10–12]. Of note, seRNA is characterized by histone modifications (H3K27ac, H3K4me1 and H3K4me2) and chromatin factors [cohesin, p300, CREB-binding protein (CBP) and RNA Pol II] [13, 14]. DNA translocations, small insertions and deletions (indels), focal amplification, single-nucleotide polymorphisms (SNPs), TFs implication and viral infections mediate aberrant SE generation, and the SE further transcribes into seRNA [15–17]. The recent studies have discovered two types of seRNA, cis-acting and trans-acting seRNA [18]. Meanwhile, according to different
transcriptional directions, seRNA is defined as 1d- and 2d-seRNA [19]. Even though, there are some overlapping regions between seRNA and ncRNA, genome-wide sequencing at transcription start site (TSS) loci can distinguish seRNA from ncRNA [20, 21]. Generally, novel technologies to identify seRNA include CHIP-seq [22], CAGE-seq [23], DNa-seq [24], GRO-seq [25], PRO-seq [26], NET-seq [27], mammalian NET-seq (mNET-seq) [28], BruUV-seq [29], and XR-seq [30].

Generally, the distance between seRNA target gene and SE is within 50 kilobase (kb). Nevertheless, there are controversies about target gene position. For one thing, SE may cover TSS of protein-coding gene, for another thing, the regulated genes might be within a segment 50 kb upstream or downstream of the SE [8]. Although actual functional specialization and evolutionary origins of seRNA still remain to be explored, accumulating observations demonstrate that seRNA expression is closely associated with target genes expression via controlling SE activity and facilitating chromatin loop [31, 32]. seRNA plays an essential role in a wide range of physiological and pathological activities. For instance, human SE-IncRNA CARMEN (Cardiac mesoderm enhancer-associated non-coding RNA) participates in cardiac specification, differentiation and homeostasis [33]. In addition, seRNA functions as an indispensable role in tumorigenesis through mediating activation of oncogenic signaling pathways, which participates in cell proliferation, autophagy, apoptosis, EMT, ECM remodeling, and angiogenesis. It has been confirmed that seRNA from urothelial cancer associated 1 (UCA1) promotes ovarian cancer development through interacting with angiomotin (AMOT) to activate yes-associated protein (YAP) signaling [34]. To comprehensively clarify the functional mechanisms of SE in promoting cancer progression, we systematically introduced seRNA generation and its characteristics, inducible factors of seRNA and their molecular mechanisms in cancer progress. And we also introduced some mysteries to be solved in seRNA research and declared perspectives in cancer therapy targeting oncogenic seRNA.

**seRNA’s characteristics and its functions**

Typically, both enhancer and promoter are classified as noncoding elements, yet recent studies indicated that active SE is a novel noncoding element and directionally transcribes into seRNA, respectively [22]. Appreciated with keynote findings, SE is defined based on the high intensity of BRD4, Med1, RNA Pol II, H3K4me1 and H3K27ac [35]. SE transcribes into a group of functional seRNA with different transcriptional modalities, structures and functions, where RNA Pol II mediates the formation of R-loop structure between seRNA and promoter [5]. Notably, some reports demonstrated that production rates of cell type-specific seRNAs mainly depend on enrichment degrees of RNA Pol II [36]. Further, integrator, a multisubunit complex with a core catalytic RNA endonuclease activity, also plays an indispensable role in biogenesis of mature seRNA and stabilization of SE-promoter chromatin loop via stably combining with C-terminal domain (CTD) of RNA Pol II. GRO-Seq and RNA Pol II profiling showed an accumulated RNA Pol II-seRNA complex and a reduced mature seRNA levels following integrator depletion [37, 38].

Similar to eRNA, seRNA belongs to a class of ncRNA. Nevertheless, there are some similarities and differences between seRNA and ncRNA. Firstly, seRNA is produced by transcription of SE region, displaying a positive correlation of seRNA transcription with histone labeling, especially with H3K27ac modification [39]. Secondly, seRNA and ncRNA have similar transcriptional characteristics at TSS, but seRNA is more unstable and has shorter half-life partly due to RNA exosome activation [40]. Thirdly, ncRNA is predominately spliced and transcribed in one direction. However, seRNA generation is based on unidirectional and bidirectional transcriptions, producing polyadenylated and non-polyadenylated seRNA, respectively [9, 38]. Lastly, SE in transcriptional state enriches transcription initiation complexes and 5-phosphate serine RNA Pol II, which has the characteristics of protein-coding genes promoter [41]. Distinctly, SE-enriched 2-phosphate serine RNA Pol II is less than the whole protein-coding genes. Most importantly, seRNA is labeled with high tissue and cell specificity, it has become one of the most interesting candidates in regulating functional interactions of SE with promoter [42].

seRNAs mainly contain polyadenylation and non-polyadenylation seRNA (Fig. 1a, b), namely polyA severna polyA severna according to the directions of transcription. PolyA severna is longer than polyA severna, and carries with lower signal ratio of H3K4me1/me3. PolyA severna is unidirectionally transcribed from SE region, also namely 1d-seRNA. While, polyA severna is termed as 2d-seRNA due to bidirectional transcription, it consists of sense and anti-sense seRNA. PolyA severna dose not undergo full maturation and lacks splicing, but it could be modified with 5’ cap [19]. Strikingly, 1d- and 2d-seRNA can simultaneously exist in some diseases, like the existence of p53-regulated 1d- and 2d-seRNA in cancer progress [20].

In addition, seRNAs can be divided into cis-acting and trans-acting seRNA according to distinct function approaches (Fig. 2a, b) [18]. Cis-acting seRNA recruits protein complexes from its synthetic site to activate adjacent genes, where the whole length or TSS of cis-acting seRNA is covered by SE [10]. In embryonic stem cells, non-polyadenylated seRNA produced at SE upstream of Nanog (~45 enhancer) regulates nearest neighbor Dppa3 (developmental pluripotency associated 3 gene) via stabilizing the looping of the distal SE at Dppa3 promoter. Depletion of seRNA reduces Dppa3 expression [43]. Moreover, a profound study has shown that seRNA could directly...
Fig. 1 1d-seRNA and 2d-seRNA transcribed from SE regulate gene expression. Active SE enriched with clusters of enhancers absorbs abundant transcription complexes including TFs, CoFs, RNA Pol II, H3K4me1 and H3K27ac modifications. a, SE unidirectionally transcribes into 1d-seRNA. b, SE induces 2d-seRNA (Anti-sense seRNA and Sense seRNA) transcription.

Fig. 2 cis-acting and trans-acting seRNAs transcribed from SE regulate gene expression. Active SE enriches TFs, CoFs, RNA Pol II, H3K4me1 and H3K27ac modifications to regulate gene expression through cis-acting and trans-acting seRNAs. a, cis-acting seRNA transcribed from SE regulates adjacent target genes expression. b, trans-acting seRNA interacts with SE originated from other chromosomes to regulate target genes expression.
interact with CBP in cis. The locus-specific binding of CBP with seRNA contributes to the elevated histone acetylation, and directly increases target gene transcription via modulating local chromatin environment [39]. The trans-acting seRNA transcribed from local genomic coordinates interacts with SE originated from other chromosomes, which significantly expands functional range of SE [44]. Remarkably, SE-derived polyadenylated alncRNA-EC7/Bloodlinc (seRNA Bloodlinc) amasses at SE to hold trans functions, subsequently boosting red blood cell production through binding with heterogeneous nuclear ribonucleoprotein U (HNRNPU) [42]. HNRNP is a nuclear matrix protein that specifically stabilizes seRNA-chromatin associations [42]. Similarly, MYOD Upstream Non-coding RNA (MUNC) is an eRNA transcribed from the upstream of MYOD enhancer. It is observed to induce the expression of specific myogenic genes, like MYOG, and (myosin heavy chain 3) MYH3 that are located on different chromosomes, indicating MUNC acting in trans [45]. According to polyadenylated seRNA Bloodlic acting in trans and non-polyadenylated seRNA acting in cis, there may be a close and complicated correlation between transcripational directions and function methods of seRNA. Taken together, cis-acting seRNA might also exert trans functions due to 3D nuclear architecture.

seRNA had previously been thought to be transcriptional noise that exerts no function due to spurious transcription from open chromatin regions [46]. Currently, it is widely accepted that seRNA exerts a powerful function in forming and stabilizing the chromatin loop, which is confirmed by chromatin conformation capture methods comprising 3C, 4C, 5C and high-throughput chromosome conformation capture (Hi-C) (Fig. 3) [47, 48]. Knockdown of seRNA would disrupt the chromatin loop [5]. Mechanically, SE produces seRNA to bind to promoter, and enhances proximal or distal genes transcription by mediating spatial interaction of SE with promoter in cooperation with RNA Pol II, cofactors (CoFs) and Med [5]. Additionally, accumulating studies have approved that cohesin complex can poise SE, and further maintain seRNA-induced loop [49]. Cohesion knockout would disturb chromosomal loop and target gene activation [50]. Amazingly, seRNA can drive out transcription inhibitory factor negative elongation factor (NELF), and transiently release it from target genes promoter [51]. Clearly, seRNA intimately augments SE function, and appears to be excellent markers of SE activity. In theory, seRNA generation is sensitive to the perturbation of SE, further affecting target genes expression [43].

**Oncogenic seRNA formation**

The aberrant seRNA generated from tumorigenesis, termed as oncogenic seRNA, modulates cancer development via maintaining chromatin loops, assembling TFs and promoting RNA Pol II activation (Fig. 4). Oncogenic seRNA, in one way, is generated from genetic alterations-induced SE, such as SNP, indels, DNA translocation, focal amplification, in other way, it is originated from somatic mutations-generated SE triggered by viral oncogenes and TFs overexpression. SNP is frequently identified within or near SE. SNP rs2168101 resides in SE of the first intron of LIM domain only 1 (LMO1), and SNP rs539846 locates in the intron 3 of B cell lymphoma 2 (BCL2)-modifying factor (BMF) SE, both of them influence neuroblastoma and chronic lymphocytic leukemia (CLL) susceptibility, respectively [52, 53]. Additionally, a single-nucleotide mutation in chromosome 4q32 (4q32A > C) is extremely rare, but this mutation attenuates SE activity and prohibits binding of POU2F1 and Yin-Yang 1 (YY1), which downregulates seRNA and enhances the predisposition of thyroid carcinoma (ATC) [54]. Obviously, SNP-activated SE could transcribe into seRNA to implicate in cancer progression.

In cancers, chromosomal translocations activate SEs to mediate dysregulated-expression of oncogenes. For
instance, chromosomal translocation t(3;8)(q27;q24) in diffuse large B cell lymphoma (DLBCL) recruits SE via MYC-BCL6 fusion gene [55], chromosomal translocation t(8;14) in myeloma transfers immunoglobulin H (IgH) SE to breakpoint at 8q24 near MYC loci [56], DNA translocation t(6;8)(p21;q24) in blastic plasmacytoid dendritic cell neoplasm (BDPCN) produces plasmacytoid dendritic cells (pDCs)-specific RUNX2 SE [57]. All of these chromosomal changes upregulate MYC proto-oncogene. Another analysis discovered that SE-induced MYC over-expression is associated with MYC seRNA-mediated R-loop maintenance [5]. In addition, putative SE and seRNA might be obtained from Indels mutations. A novel report demonstrated that the deletions linked with MYC actively generate SE to further augment MYC expression in multiple myeloma (MM) [58], and the existence of MYC seRNA had been approved [5]. In T cell acute lymphoblastic leukemia (T-ALL), short insertion mutations in noncoding intergenic region of TAL1-specific SE produce a de novo myeloblastosis oncogene (MYB) TF binding motif, followed by the recruitment of MYB and H3K27ac-binding CBP, which is important for SE initiation, seRNA transcription, and TAL1 oncogene expression [16]. Notably, focal amplification of enhancer elements frequently occurs in various cancers, which actually accelerates noncoding genes transcription [59]. The two different focal amplifications of SE 3’ to MYC in lung adenocarcinoma and endometrial carcinoma activate and boosts MYC promoter, which depends on lineage-specific chromatin loops and seRNA generation [7]. Additionally, recurrent focal amplification at chromosome 8q24 forms a NOTCH-bound MYC SE and drives MYC transcription, which might involve with MYC seRNA generation [60]. Thereby, focal amplification might participate in cancer development via promoting seRNA-mediated oncogene expression.

Currently, viral infection is identified to be a chief biological pathogenic factor to facilitate oncogenic SE and seRNA generation. Integration of human papillomavirus (HPV) genomes into cellular chromatin is frequent in HPV-associated cancers [61]. Tandemly integrated HPV16 could result in viral-cellular SE element formation [62], which mediates seRNA HOTAIR transcription and enhances E6 and E7 expression, causing cervical cancer pathogenesis [63]. Epstein-Barr virus (EBV) infection promotes EBV-induced SE (ESE) looping, leading to continuous proliferation of lymphoblastoid cell lines (LCLs) [64]. Gro-seq data of LCLs showed that affluent seRNA transcribed at MYC ESE promotes MYC oncogene expression [5]. Interestingly, EBV infection also induces nasopharyngeal carcinoma (NPC)-specific SE generation in ETV6 introns and coding regions, which increases ETV6 expression correlated with poor prognosis [65]. It has well been established that human immunodeficiency virus type 1 (HIV-1) recurrently activates target genes via integrating into proximity of SE in CD4 + T cells [66]. Actually, interferon-regulatory factor 1 (IRF1)/nuclear factor kappa-B (NF-κB) complex at the SE sites is necessary for full HIV-1 SE site-mediated seRNA transcription [67]. Additionally, human lymphotropic virus type I (HTLV-I) is frequently incurable in adult T cell leukemia/lymphoma (ATLL). HBZ and HTLV-I-encoded TFs integrate into ATLL-specific BATF3 SE, further enhancing MYC expression by linking with BATF3/IRF4. Overexpressed MYC exacerbates disease through MYC seRNA transcription [68]. Interestingly, the nuclear matrix protein SAFA (also known as HNRNPU) displays an antiviral function by promoting immunity and stimulating productions of SE and seRNA of antiviral genes, including type I IFNs [69]. Of crucial note, integrating of overexpressed TFs in SE is
Functions and mechanisms of oncogenic seRNA in cancer progress

Although the biological function of seRNA still remains poorly characterized, some interesting observations have evidently indicated that seRNA promotes target gene transcription not only to participate in physiological activity, but also to involve in tumorigenic action, including oncogene expression, cancer cell proliferation, EMT, ECM remodeling, angiogenesis, immune response, apoptosis and autophagy (Fig. 5, Table 1).

seRNA promotes oncogene expression

Oncogenic seRNA functions as a significant regulatory factor for targeting oncogene transcription (Fig. 5). It has been verified that oncogenic EBV infection controls B cells growth and drives lymphoma and carcinoma development via inducing seRNA production and oncogenic MYC expression [64]. Gro-seq data of LCLs revealed that abundant seRNAs transcribed at MYC ESE promote transcriptional activation of MYC oncogene. While knockdown of MYC seRNA significantly attenuates MYC expression via inhibiting MYC ESE looping to MYC TSS [5]. In general, seRNA can recruit TFs to maintain chromatin loops. For instance, colorectal cancer (CRC)-specific seRNA CCAT1-L is classified as a nuclear-retained IncRNA, and 3C analysis showed that CCAT1-L locates at 335 kb upstream of MYC promoter (MYC-335). There is a strongest chromatin interaction between MYC-335 and the MYC promoter, while the interaction between MYC-515 and MYC-355 ranks in the second. Interestingly, CCAT1-L cis overexpression remarkably upregulates MYC and accelerates CRC tumorigenesis [32]. Further investigation revealed that CCCTC-binding factor (CTCF) is enriched at the loops of MYC promoter and the MYC-335 and MYC-515 segments, and there is a specific interaction between CTCF and CCAT1-L. CTCF knockdown significantly decreases the transcription of MYC and CCAT1-L. Moreover, depletion of CCAT1-L markedly decreases CTCF occupation of loop regions at MYC. It could be speculated that CCAT1-L may regulate MYC expression by interacting with CTCF, which stabilizes long-range chromatin interactions of MYC promoter with MYC-335 or interaction of MYC-335 with MYC-515 [32]. Additionally, T-ALL-related TAL1 [16], Ewing sarcoma-related MEIS1 [100], hepatocellular carcinoma (HCC)-correlated sphingosine kinase 1 (SPHK1) [101], HPV-induced E6 and E7 [61], oral squamous cell carcinoma (OSCC)-associated PAK4, RUNX1, DNAJB1, SREBF2 and YAP1 [102] are correspondingly regulated by oncogenic SE, and promote cancer development.
seRNA participates in cancer cell proliferation

Oncogenic seRNA promotes cancer cells proliferation through regulating signal molecules expression and activating signal-pathways (Fig. 5). CCAT1 seRNA is proved to be a significant biomarker in CRC, abundant studies have proved that it is also upregulated in different cancers, such as bladder cancer [73], esophageal cancer [74], cervical cancer [74], prostate cancer [103], and ovarian cancer [75]. In particular, squamous cell carcinoma (SCC) specific SE regions are cooperatively occupied with TP63 and SOX2 to boost CCAT1 seRNA transcription, CCAT1/TP63/SOX2 complex is bound to SE regions of epidermal growth factor receptor (EGFR) to promote EGFR transcription. The overexpressed EGFR contributes to the activation of RAF/mitogen-activated extracellular signal-regulated kinase (MEK)/ERK1/2 and PI3K/ASK signaling pathways, and boosts SCC cell proliferation both in vitro and in vivo [24]. Experimentally, CCAT1 knockdown significantly decreases cell proliferation and colony growth, and reduces volume and mass of the xenografted tumors in vivo, CCAT1 highlights a strong oncogenic potential in SCC cells.

Interestingly, SE regions of several cancer-correlated genes can directly produce seRNA. TIAM2 was identified as an uncharacterized gene in ATL, its overexpression promoted cell proliferation via inducing SE and seRNA activation [104]. CDK inhibitor, THZ1, efficiently downregulates the expression of SE-associated TIAM2 and inhibits cell growth. On the contrary, TP53, a tumor suppressor, might produce seRNA from SE regions at
p53-dependent manner. The seRNA produced from TP53 SE regions strengthens efficient TP53 transcription and induces p53-dependent cell-cycle arrest, showing the potent function of TP53 SE-transcribed seRNA in suppressing cancer cells proliferation [99]. Collectively, seRNAs transcribed from SE may play a dual role in cancer cells proliferation, but this needs more direct evidence.

### seRNA exerts dual-functions of apoptosis and antiapoptosis

seRNA exerts a apoptosis regulator through modulating several apoptosis mediators such as Bax and Bcl-2 (Fig. 5). seRNA UCA1 highly expresses in various cancers including gastric and ovarian cancer. The direct binding of seRNA UCA1 to AMOT p130 enhances AMOTp130-YAP interaction, which prominently activates Hippo-YAP signaling via promoting YAP phosphorylation and nuclear translocation [34, 94]. YAP activation significantly upregulates proapoptotic protein Bax expression, downregulates antiapoptotic protein Bcl-2 expression (Fig. 5). The increased Bax/Bcl-2 ratio exerts proapoptosis function in neuroblastoma (NB) and gastric cancer (GC) [77, 78]. Interestingly, activation of mitogen-activated protein kinase (MAPK) signaling inhibits YAP phosphorylation and promotes YAP nuclear translocation via upregulating c-Jun N-terminal kinase (JNK) and extracellular signal regulated kinase (ERK). Hence, the crosstalk between Hippo-YAP and MAPK signaling pathway cooperatively takes part in the regulation of apoptosis behavior in cancer progress [59].

Upon apoptosis stimuli, Bak and Bax form complex, and the accumulation of Bak protein on mitochondrial outer membrane further boosts apoptosis by stimulating the release of proapoptotic proteins from mitochondria into cytosol [105]. To our surprise, SE inhibitors, JQ1 and THZ1, have a potent capability to trigger cancer cells apoptosis accompanied with increased Bax [106], suggesting that SE might block cancer cells apoptosis via upregulating seRNA and proapoptotic protein expression. Thereby, the exact contribution of seRNA to apoptosis might be a “double-edged sword”, and this remains to be explored (Fig. 5).

### seRNA participates in autophagy regulation

Recent studies have found that seRNA expression is tightly associated with autophagy. seRNA UC1A1-activated Hippo-YAP is associated with not only apoptosis, but also autophagy. Increased Hippo-YAP activation has been found to control autophagy, which involves in mammalian target of rapamycin (mTOR) pathway that is a notable regulator of autophagy [107]. A study on breast carcinoma MCF-7 cells confirmed that scutellarin treatment upregulates p-YAP and downregulates YAP levels, which represses cancer development via inducing autophagy [79]. Oppositely, UCA1-induced Hippo-YAP activation could suppress autophagy and exacerbate cancer process [80]. SCC-specific seRNA LINC01503 is activated when TF TP63 is bound to SE at seRNA locus, further enhancing malignant phenotype of SCC. Mechanically, overexpressed LINC01503 interacts with ERK2, which leads to activation of ERK/p38 MAPK signaling through inhibiting the binding of ERK2 with dual specificity phosphatase 6 (DUSP6) and reducing ERK2 dephosphorylation (Fig. 5). Similarly, the interaction of LINC01503 with enhancer binding protein (EBP1) disrupts the binding of EBP1 to p85 subunit of PI3K and promotes PI3K ubiquitination, subsequently activating PI3K/AKT signaling. The two signaling pathways synergistically accelerate autophagy and strengthen oncogenic activity of SCC [80, 81]. In addition, the enhancer of zeste homolog 2 (EZH2) mediates p38 MAPK activation via directly binding with seRNA, and the activated EZH2 induces autophagy through promoting p38 MAPK phosphorylation, following the upregulated autophagy genes including Agt5 and LC-3II [108, 109] (Fig. 5). Disturbance of autophagy-lysosome flux leads to endoplasmic reticulum (ER) stress and an unfolded protein response (UPR), which finally leads to apoptotic cell death in the tumor tissue [110]. In particular, genome stress with temozolomide (TMZ) synergistically induces apoptosis in collaboration with accumulated ER stress with chloroquine treatment [111].

### seRNA mediates EMT of cancer cell

EMT is a reversible trans-differentiation of polarized epithelial cells to mesenchymal cells, which is involved with embryogenesis, wound healing, oncogenes and tumor-suppressor genes expression [112]. Increasing reports indicated that dysregulated seRNA impacts epithelial plasticity by affecting various EMT markers expression (Fig. 5). CRC-specific seRNA CCAT1-L has been proved to be overexpressed in various cancers including bladder, cervical and ovarian cancer, it promotes EMT activation, invasion and metastasis [73–75]. seRNA HCCL5 is considered as an SE-driven cytoplasmic lncRNA in HCC, and it accelerates EMT phenotype, invasion and metastasis in HCC cells by up-regulating Snail, Slug, ZEB1 and Twist1 expression [72]. Interestingly, SE-induced circRNA participates in regulating EMT process. A profound study has discovered that nuclear TF YY1 is bound to SE to build YY1/p65/p300 complex, which facilitates SE-associated circRNA generation to promote the malignancy of HCC [76].

Beyond all doubt, seRNA-correlated oncogenes also exert a positive part in EMT process. CTNNFD1 (delta-catenin) functions as a novel oncogene in HCC. Notably, knockdown of CTNNFD1 prominently leads to mesenchymal-epithelial transition (MET), whereas its overexpression
enhances EMT and metastatic and invasive properties of HCC via indirectly modulating Wnt/β-catenin signaling, accompanied with increased cyclin D1 and matrix metalloproteinase (MMP)-7 [113, 114]. Previous study has found that canonical Wnt/β-catenin signaling enhances metastasis of cancer cells by up-regulating ZEB1 in vitro [115]. Thus, seRNA may induce CTNND1 further to stimulate Wnt/β-catenin signaling and promote EMT formation through activating ZEB1.

**seRNA regulates cancer angiogenesis**

Angiogenesis accelerates cancer progress via providing nutrient and energy supply, thus it frequently serves as a therapeutic target for cancer [116]. Oncogenic seRNA regulates cancer angiogenesis through activating several signaling pathways (Fig. 5). SE-associated Nfix circRNA (circNfix), namely seRNA Nfix, activates glycogen synthase kinase-3β (GSK-3β) pathway to promote angiogenesis [12, 76]. seRNA-activated PI3K/AKT signaling can not only promote autophagy, but also accelerate angiogenesis in anaplastic ATC and renal cell carcinoma (RCC) through triggering GSK3β/ANG and GSK3β/AM pathway activation [82, 83]. Additionally, GSK3β/β-catenin signaling pathway also enhances angiogenesis through mediating vascular endothelial growth factor (VEGF) expression [117].

In addition, there are other signal pathways that are involved in angiogenesis. seRNA UCA1-activated Hippo-YAP signaling has been proved to induce angiogenesis in pancreatic ductal adenocarcinoma (PDAC) via enhancing Ang2, VE-cadherin and α-smooth muscle actin (α-SMA) expression [84]. seRNA directly binds with EZH2, and the seRNA/EZH2 complex recruits methyl groups to the promoter region of angiogenesis inhibitor gene vashohbin-1 (VASH1), then the reduced VASH1 expression facilitates angiogenesis [118].

**seRNA participates in immune response**

Cell specific seRNAs implicate in proliferation, differentiation, maturation and activation of immune cells and secretion of cytokines (Fig. 5). seRNA existed in CD4+ T and foxp3+ regulatory T (Treg) cells plays an important role in T and Treg cells differentiation, maturation and function, respectively [85, 86]. It has been proved that IgH 3’ regulatory region (3’RR) acts as a major B-cells SE [87], the target genes closer to seRNA are more highly expressed in human humoral immune B cells [88]. Fusion gene ETV6-RUNX1-generated SE induces seRNA generation that is considered as a pivotal marker for CD19+/CD20+ cells at later stage of B cells differentiation, which is linked with B cells maturation [89]. In macrophages, lipopolysaccharide (LPS)-activated toll-like receptor 4 (TLR4) signaling can facilitate nearly all SE to express seRNA (93.3%) in intergenic regions via recruiting TFs binding, together with overexpression of key genes that drive the releases of innate immunity and inflammatory factor, like IFN-γ [90]. Importantly, IFN-γ seRNA maintains the interaction of NF-κB with IFN-γ locus, which boosts innate and adaptive immune responses against cancer progression [119]. Preclinical data showed that BET inhibitor JQ1 prominently abrogates BRD4-associated IFN-γ seRNA and IFN-γ production via suppressing RNA Pol II binding to the IFN-γ locus, which results in dysfunction of CD4+ T and NK cells, following by the weak immune response [91].

In addition, seRNA manipulates the expression of immune checkpoints, including stimulatory and inhibitory checkpoints [120]. For example, seRNA CCAT1-L-induced MYC upregulates the expression of innate immune checkpoint CD47 (cluster of differentiation 47) and adaptive immune checkpoint PD-L1 (programmed death-ligand 1) by directly interacting with promoters of these two genes in cis [93]. Moreover, the CCAT1/TP63/SOX2 complex binds to SE sites of EGFR to enhance EGRF transcription in trans [24], further increasing PD-L1 expression by activating PI3K/AKT and RAF/MEK/ERK signaling. Taken together, seRNA CCAT1 could heighten PD-L1 transcription by forming an seRNA-TF complex to promote target genes expression and stimulate downstream signaling pathways [92]. seRNA-associated IFN-γ signaling primarily induces PD-L1 expression in melanoma cells through activating Janus kinase (JAK)-signal transducer and activator of transcription (STAT)-IRF1 axis [121].

It has been demonstrated that BRD is an extremely important constituent of SE, treatment with BRD inhibitors or BRD4 knockdown suppresses PD-L1 expression in ovarian cancer [122]. As being described previously, BRD4 promotes seRNA transcription, and there is a chromatin loop between distal SE and PD-L1 TSS. Therefore, seRNA might be involved in BRD4-mediated PD-L1 up-regulation by maintaining the chromatin loop [123]. Collectively, seRNA suppression mediated by BRD4 inhibitors might promote anticancer immunity by suppressing PD-L1 expression or block anticancer immunity through inactivating immune cells.

**seRNA involves in ECM remodeling**

ECM is a crucial component of tumor microenvironment (TME) and an important barrier for invasion and metastasis [124]. seRNA can directly or indirectly influences ECM remodeling via regulating ECM proteins transcription (Fig. 5). Nowadays, several lncRNAs enriched at SE regions have been identified in hepatic stellate cells (HSCs), which are unidirectional seRNAs that encode key genes to regulate ECM stiffness [125]. Currently, a novel study focused on the function of seRNA UCA1-activated YAP, and discovered that aberrant activation of YAP/TAZ (transcriptional
coactivator with PDZ-binding domain) axis exists in the microenvironment of various cancers including GC, CRC, lung cancer and breast cancer [94]. YAP/TAZ activation remarkably increases contractile activity and upregulates connective tissue growth factor (CTGF) and Cyr61, which promotes α–SMA overexpression and ECM proteins deposition including laminin, collagen type I and fibronectin [126]. Of critical note, SE-boosted seRNA might drive cancer-associated fibroblasts (CAF) proliferation and myofibroblast differentiation [96]. This process also accompanies with degradation and remodeling of ECM via secreting MMP-2 and 9 and boosting TGF-β1/FAK/RhoA signaling, which accelerates the invasion and metastasis of breast cancer [97, 98]. Amazingly, there is a positive feedback loop between stiff ECM and CAFs activation [95].

As mentioned previously, the pathological role of CAFs in TME was used to consider as a therapeutic strategy for preventing cancer development and progression [127]. Typically, CAFs produce excessive amounts of fibrous collagen, which can be cross-linked by lysyl oxidase (LOX), then increasing focal adhesions and ECM stiffness [128, 129]. In turn, the increased ECM stiffness was identified to profoundly facilitate cancer progression through triggering oncogenic signal pathways including activated focal adhesion kinase (FAK), β-catenin, and PI3K/AKT [129, 130]. Functionally, targeting ECM stiffness via inhibiting LOX enzymatic activity and repressing CAFs proliferation and subsequent CAFs–neoplastic cells interaction, have been demonstrated to decrease metastatic dissemination of breast and colorectal tumor cells in vivo [102, 129].

Of note, PLX4720 (BRAF inhibitor) also leads to activation of CAFs and enhancement of matrix remodeling via negatively affecting BRAF expression. The remodeled matrix enables melanoma cells to tolerate PLX4720 via stimulating integrin β1/FAK-dependent ERK/MAPK signaling [131]. More importantly, the patient-derived tumor xenografts (PDXs) model revealed that co-inhibition of BRAF and FAK abolishes ERK reactivation in tumor stroma [132].

**Challenge and prospective**

Recently, seRNA emerges in lots of hot fields due to its wide and strong functions in universal conditions. 3D nuclear architecture studies suggested that seRNA may not only play a role in linear nearby genes expression, but also affect the linear distant genes expression. CRISPR/Cas9 genome-editing technology by disrupting SE functional fragments provides new insights for the exploration of seRNA [133]. In the study on seRNA, several challenges still lie ahead. For instance, transcripts from seRNA are unstable and frequently aborted, which brings immense challenges to find more significant seRNA and validate the corresponding functions [29]. Thereby, future study should focus on postponing seRNA decay, which might involve in RNA metabolism and RNA regulatory pathways [134]. Moreover, it still needs to be verified whether the stability of SE-promoter interaction impacts seRNA stability via regulating the efficiency of recruiting RNA Pol II and other important TFs.

Numerous models have proposed abroad and powerful biological function of seRNA, but the detailed molecular mechanisms of seRNA actually remain to be explored. It is well established that seRNA forms and maintains R-loop to promote adjacent or distant target gene

Table 2: Combinational therapies with SE inhibitors in clinical trials

| Drug name          | Target | Combination                | Disease                                      | Status       | Phase            | NCT number   |
|--------------------|--------|----------------------------|----------------------------------------------|--------------|------------------|--------------|
| FT-1101            | BET    | Azacitidine                | AML, MDS or non-hodgkin lymphoma (NHL)       | Completed    | 1                | 02543879     |
| CPI-0610           | BET    | Ruxolitinib                | Myelofibrosis                                | Recruiting   | 2                | 02158858     |
| BMS-986158         | BET    | Nivolumab                  | Advanced tumors                              | Recruiting   | 2                | T02419417    |
| RO6870810          | BET    | Daratumumab                | Relapsed/refractory multiple myeloma         | Active, not  | Recruiting       | 1            | 03068351     |
| SY-1365            | CDK7   | Carboplatin or Fulvestrant | Advanced solid tumors, ovarian cancer, breast cancer | Recruiting   | 1                | 03134638     |
| CT7001             | CDK7   | Fulvestrant                | Advanced solid malignancies                  | Recruiting   | 2                | 03363893     |
| BCD-115            | CDK8/19| Endocrine therapy          | Breast cancer                                | Completed    | 1                | 03065010     |
| PD-0332991/        | CDK4/6 | Binimetinib                | Lung cancer                                  | Recruiting   | 1                | 03170206     |
| Palbociclib         |        |                            |                                              |              |                  |              |
| LEE011/Ribociclib   | CDK4/6 | Ceritinib                  | Non-small cell lung cancer                   | Completed    | 1                | 02292550     |
| PD-0332991/        | CDK4/6 | Nab-Paclitaxel             | Metastatic pancreatic ductal adenocarcinoma | Completed    | 1                | 02501902     |
| Palbociclib         |        |                            |                                              |              |                  |              |
| Trilaciclib /GT28  | CDK4/6 | Etoposide and Carboplatin  | Small cell lung cancer                       | Completed    | 1b/2a            | 02499770     |

*BET bromodomain and extra-terminal, CDK cyclin-dependent kinases. The data originated from: https://clinicaltrials.gov*
expression. Notably, the maintained presence of chromatin loop between SE and TSS could facilitate transcription initiation. However, it is put forward that seRNA might negatively regulate target genes expression. Since seRNA extensively exerts functions, its transcription might lead to some unknown alterations of physiological activities, this is difficult to be investigated. seRNA is mainly composed of 1d and 2d-seRNA, or cis-acting and trans-acting seRNA, moreover, abundant polyA+ 1d-seRNA accumulated at SE would hold trans functions [42]. Maybe, there is profound association between transcriptional direction and functional methods of seRNA. Therefore, distinguished functional mechanisms of seRNA are really worthy of a profound exploration.

In tumorigenesis, DNA damage response (DDR), gene mutations, and genome instability are associated with seRNA formation and alteration [134], which might lead to abnormal genes expression and drive malignant progress of cancer. Theoretically, seRNA has potential to become a better biomarker for diagnosing cancer than frequently used biomarkers such as mRNA, DNA or protein, and it also presents a novel therapy target for cancer due to the high cell specificity [135]. A wide range of preclinical studies suggest that SE inhibitors, such as BRD4 inhibitor JQ1 [136], CDK7 inhibitor THZ1 [137], mediator-associated CDK8 inhibitor cortistatin A [138], CDK12 inhibitor THZ531 [139] and CDK4/6 inhibitor LEE011 [140], have shown dramatic potential for suppressing seRNA transcription and inhibiting cancer growth. As shown in Table 2, combination therapies with SE inhibitors have entered into clinical trials, which provide a deep insight for anticancer therapy. In addition, considering the structural characteristics of SE, future research should pay attention to elucidate the functions of individual components of SE [135].

**Conclusion**

Collectively, seRNA derived from active SE has a powerful transcriptional regulation function, and its production rate is based on the recruitment of RNA Pol II. Significantly, seRNA regulates near gene transcription and mediates distant gene expression via forming and maintaining the chromatin loop of SE and promoter. During tumorigenesis, DNA insertion, deletion, translocation, focal amplification and carcinogen factor mediate oncogenic SE generation, and oncogenic SE transcribes into oncogenic seRNA. Oncogenic seRNA activates multiple signaling pathways that are associated with cell proliferation, EMT, apoptosis, autophagy, ECM remodeling, angiogenesis, and immune response, promoting carcinogenesis. SE inhibitors are capable of blocking seRNA generation via disrupting SE to suppress oncogenic signaling pathways, therefore, targeting seRNA might represent new strategies for cancer therapy.

**Abbreviations**

AMOT: Angiomotin; α-SMA: α-smooth muscle actin; ATC: Anaplastic thyroid carcinoma; ATLL: Adult T cell leukemia/lymphoma; BET: Bromodomain and extra-terminal; BFMC: B cell lymphoma 2 (BCL2)-modifying factor; BPDEN: Blastic plasmacytoid dendritic cell neoplasms; BRD4: Bromodomain-containing protein 4; BruuV-seq: Bromouridine ultraviolet sequencing; CAFs: Cancer associated fibroblasts; CAGE-seq: Cap analysis of gene expression sequencing; CBP: CREB-binding protein; CCAT1-L: Colon cancer associated transcript 1; CD47: Cluster of differentiation 47; CHIP-seq: Chromatin immunoprecipitation followed by sequence analysis; circlipfx: Nix cirRNA; cir(ArrayList: Circular RNA; CLL: Chronic lymphocytic leukemia; CoFs: Co-factors; COQ: Chloroquine; CRC: Colorectal cancer; CTF: CCCTC-binding factor; CTID: C-terminal domain; DLBCL: Diffuse large B cell lymphoma; DNase-qseq: DNase I hypersensitive sites sequencing; DUSP6: Dual specificity phosphatase 6; EBV: Enhancer binding protein; EBV: Epstein–Barr virus; ECM: Extracellular matrix; EMT: Epithelial–mesenchymal transition; eRNA: Enhancer RNA; ESCs: Embryonic stem cells; EZH2: Enhancer of zeste homolog 2; FAK: Focal adhesion kinase; GC: Gastric cancer; GRO-seq: Global nuclear run-on sequencing; H3K4me1: Histone H3 lysine 4 monomethylation; H3K27ac: Histone H3 lysine 27 acetylation; HCC: Hepatocellular carcinoma; Hi-C: High-throughput chromosome conformation capture; HNRRPU: Heterogeneous nuclear ribonucleoprotein U; HSCs: Hepatic stellate cells; HTLV-I: Human lymphotropic virus type I; Indels: Insertions and deletions; IRF1: Interferon-regulatory factor 1; JAK: Janus kinase; LCLs: Lymphoblastoid cell lines; IncRNA: Long noncoding RNA; Lox: Lysyl oxidase; LPS: Lipopolysaccharide; MED: Mediator; MEK: Mitogen-activated extracellular signal-regulated kinase; MET: Mesenchymal-epithelial transition; MYB: Myeloblastosis oncogene; MYH3: Myosin heavy chain 3; NB: Neuroblastoma; ncRNA: Noncoding RNA; NELF: Negative elongation factor; NET-seq: Native elongating transcript sequencing; NPC: Nasopharyngeal carcinoma; PARP: Poly ADP-ribose polymerase; PDAC: Pancreatic ductal adenocarcinoma; PDCA: Pancreatic ductal adenocarcinoma; PDK1: Phosphorylated elongin; PD-L1: Programmed death-ligand 1; PDXs: Patient-derived tumor xenografts; Pol II: Polymerase II; PRO-seq: Precision nuclear run-on sequencing; RCC: Renal cell carcinoma; ROSE: Rank ordering of SE; SCC: Squamous cell carcinoma; SE: Super-enhancer; seRNA: Super enhancer RNA; SPHK1: Sphingosine kinase 1; STAT: Signal transducer and activator of transcription; TAZ: Transcriptional coactivator with PDZ-binding domain; TEs: Transcription factors; TLB4: Toll-like receptor 4; TME: Tumor microenvironment; TMZ: Temozolomide; TSS: Transcription start site; Treg: Foxp3+ regulatory T; UCA1: Urothelial cancer associated 1; VASH1: Vasohibin-1; XR-seq: Excision repair sequencing; CBP: CREB-binding protein; CCAT1-L: Colon cancer associated transcript 1; CD47: Cluster of differentiation 47; CHIP-seq: Chromatin immunoprecipitation followed by sequence analysis; circlipfx: Nix cirRNA; cir(ArrayList: Circular RNA; CLL: Chronic lymphocytic leukemia; CoFs: Co-factors; COQ: Chloroquine; CRC: Colorectal cancer; CTF: CCCTC-binding factor; CTID: C-terminal domain; DLBCL: Diffuse large B cell lymphoma; DNase-qseq: DNase I hypersensitive sites sequencing; DUSP6: Dual specificity phosphatase 6; EBV: Enhancer binding protein; EBV: Epstein–Barr virus; ECM: Extracellular matrix; EMT: Epithelial–mesenchymal transition; eRNA: Enhancer RNA; ESCs: Embryonic stem cells; EZH2: Enhancer of zeste homolog 2; FAK: Focal adhesion kinase; GC: Gastric cancer; GRO-seq: Global nuclear run-on sequencing; H3K4me1: Histone H3 lysine 4 monomethylation; H3K27ac: Histone H3 lysine 27 acetylation; HCC: Hepatocellular carcinoma; Hi-C: High-throughput chromosome conformation capture; HNRRPU: Heterogeneous nuclear ribonucleoprotein U; HSCs: Hepatic stellate cells; HTLV-I: Human lymphotropic virus type I; Indels: Insertions and deletions; IRF1: Interferon-regulatory factor 1; JAK: Janus kinase; LCLs: Lymphoblastoid cell lines; IncRNA: Long noncoding RNA; Lox: Lysyl oxidase; LPS: Lipopolysaccharide; MED: Mediator; MEK: Mitogen-activated extracellular signal-regulated kinase; MET: Mesenchymal-epithelial transition; MYB: Myeloblastosis oncogene; MYH3: Myosin heavy chain 3; NB: Neuroblastoma; ncRNA: Noncoding RNA; NELF: Negative elongation factor; NET-seq: Native elongating transcript sequencing; NPC: Nasopharyngeal carcinoma; PARP: Poly ADP-ribose polymerase; PDAC: Pancreatic ductal adenocarcinoma; PDCA: Pancreatic ductal adenocarcinoma; PDK1: Phosphorylated elongin; PD-L1: Programmed death-ligand 1; PDXs: Patient-derived tumor xenografts; Pol II: Polymerase II; PRO-seq: Precision nuclear run-on sequencing; RCC: Renal cell carcinoma; ROSE: Rank ordering of SE; SCC: Squamous cell carcinoma; SE: Super-enhancer; seRNA: Super enhancer RNA; SPHK1: Sphingosine kinase 1; STAT: Signal transducer and activator of transcription; TAZ: Transcriptional coactivator with PDZ-binding domain; TEs: Transcription factors; TLB4: Toll-like receptor 4; TME: Tumor microenvironment; TMZ: Temozolomide; TSS: Transcription start site; Treg: Foxp3+ regulatory T; UCA1: Urothelial cancer associated 1; VASH1: Vasohibin-1; XR-seq: Excision repair sequencing; YAP: Yes-associated protein; YY1: Yin-Yang 1

**Acknowledgements**

We thank the members in Clinical Laboratory of Hunan Cancer Hospital and Xiangya Medical School of Central South University for contributions and Dr., Dong Z in Hormel Institute of University of Minnesota helpful discussion.

**Authors’ contributions**

Tan Y wrote the paper. Li Y revised the paper. Tang F designed and revised the paper. The author(s) read and approved the final manuscript.

**Funding**

This work was supported in part by the National Natural Science Foundation of China (81872226, 81502346), Hunan Provincial Natural Science Foundation of China (2018J6131, 2019JJ40175), Changsha Science and Technology Bureau of Hunan Provincial Natural Science Foundation (81872226, 81502346), Hunan Provincial Natural Science Foundation (B2019084).

**Availability of data and materials**

All data generated or analysed during this study are included in this published article and its supplementary information files.

**Ethics approval and consent to participate**

Not applicable for this section.

**Consent for publication**

The authors confirmed that we are consent for publishing the manuscript.
Competing interests

The authors declare that they have no competing interests.

Received: 29 December 2019 Accepted: 30 March 2020
Published online: 11 April 2020

References

1. Luo Z, Lin C. Enhancer, epigenetics, and human disease. Curr Opin Genet Dev. 2016;36:227–33.
2. Caño E, Wysocka J. Modification of enhancer chromatin: what, how, and why? Mol Cell. 2013;49:825–37.
3. Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-Andre V, Sigova AA, Hoke HA, Young RA. Super-enhancers in the control of cell identity and disease. Cell. 2013;153:934–47.
4. Whyte WA, Ollier DA, Hnisz D, Abraham BJ, Lin CY, Kagey MH, Rahl PB, Lee TI, Young RA. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell. 2013;153:307–19.
5. Yang Y, Su Z, Song X, Liang B, Zeng F, Chang X, Huang D. Enhancer RNA-driven looping enhances the transcription of the long noncoding RNA DHR54-AS1, a controller of the DHR54 gene cluster. Sci Rep. 2016;6:20661.
6. Peng Y, Zhang Y. Enhancer and super-enhancer: positive regulators in gene transcription. Animal Model Exp Med. 2018;8:169–79.
7. Zhang X, Choi FS, Francis JM, Imleri M, Watanabe H, Chemiack AD, Meyerson M. Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers. Nat Genet. 2016;48:176–82.
8. Niedenfert AR, Varshney A, Parker SC, Martin DM. Super enhancers in cancers, complex disease, and developmental disorders. Genes (Basel). 2015;6:1189–200.
9. Mao R, Wu Y, Ming Y, Yu Y, Wang S, Chen X, Wang X, Fan Y. Enhancer RNAs: a missing regulatory layer in gene transcription. Sci China Life Sci. 2019;62:905–12.
10. Soibam B. Super-IncRNAs: identification of IncRNAs that target super-enhancers via RNA:DNA:RNA triplex formation. RNA. 2017;23:1729–42.
11. Suzuki H, Young RA. Sharp PA. Super-enhancer-mediated RNA processing revealed by integrative MicroRNA network analysis. Cell. 2017;168:1000–14 e1015.
12. Huang S, Li X, Zheng H, Si X, Li B, Wei G, Li C, Chen Y, Chen Y, Liao W, et al. Loss of super-enhancer-regulated circRNA Nfix induces cardiac regeneration after myocardial infarction in adult mice. Circulation. 2019;139:2857–76.
13. Onzunzain, S. Pezzuto J, Micheli R, Burdet F, Sheta R, Nemir M, Gonzales C, Sarre A, Alexanian M, Blow MJ, et al. Functional importance of cardiac enhancer-associated noncoding RNAs in heart development and disease. J Mol Cell Cardiol. 2014;7:653–70.
14. Rothchild G, Basu U. Lingerling questions about enhancer RNA and enhancer transcription-coupled genomic instability. Trends Genet. 2017;33:143–54.
15. Cong Z, Li Q, Yang Y, Guo X, Cui L, You T. The SNP of rs6854845 suppresses regulated enhancer RNAs uncovers a subset of enhancers controlled by a super-enhancer-associated long noncoding RNA controlling cardiac specification, differentiation and homeostasis. J Mol Cell Cardiol. 2013;55:989–112.
16. Lin X, Spindler TJ, de Souza Fonseca MA, Corolla RI, Seo JH, Dezem FS, Li L, Lee JM, Long HW, Sellers TA, et al. Super-Enhancer-Associated LincRNA UCA1 Interacts Directly with AMOT to Activate YAP Target Genes in Epithelial Ovarian Cancer. iScience. 2019;17:242–55.
17. Huang PP, Brusman LE, Iyer AK, Webster NJ, Mellon PL. A novel gadonotriparin-releasing hormone 1 (GnR1) enhancer-derived noncoding RNA regulates GnR1 gene expression in GnRH neuronal cell models. PLoS One. 2011;6:e19587.
18. Pulakanti K, Pinello L, Stelloh C, Blinka S, Allred J, Milanovich S, Kiblawi S, Lynch CJ, Bernad R, Calvo I, Nobrega-Pereira S, Ruiz S, Ibarz N, Martinez-Val One. 2016;11:e0158597.
19. Zandian R, Hayes M, Johannsen E. CAGE-seq analysis of Epstein-Barr virus lytic gene transcription: 3 kinetic classes from 2 mechanisms. PLoS Pathog. 2018;14:e1007114.
20. Jiang Y, Jiang YY, Xie JJ, Mayakonda A, Hazawa M, Chen L, Xiao JF, Li CQ, Huang ML, Ding LW, et al. Co-activation of super-enhancer-driven CCAT1 by TPE3 and SOX2 promotes squamous cancer progression. Nat Commun. 2018;9:3619.
21. Chae M, Danko CG, Kraus WL. groHM甲: a computational tool for identifying unannotated and cell type-specific transcription units from global run-on sequencing data. BMC Bioinformatics. 2015;16:222.
22. Zhao Y, Liu Q, Acharya P, Stengel KR, Sheng Q, Zhou X, Kwak H, Fischer MA, Bradner JE, Strickland SA, et al. High-resolution mapping of RNA polymerases identifies mechanisms of sensitivity and resistance to BET inhibitors in t(8;21) AML. Cell Rep. 2016;12:2003–16.
23. Mylonas C, Tessler P. NET-prism enables RNA polymerase-directed transcriptional interrogation at nucleotide resolution. RNA Biol. 2019;16:1156–65.
24. Szalacha K, Thys RG, Atkin ND, Pierce LCT, Bekiranov S, Wang YH. Alternative DNA secondary structure formation affects RNA polymerase II promoter-proximal pausing in human. Genome Biol. 2018;19:89.
25. Magnuson B, Veloso A, Kirkconnell KS, de Andrade Lima LC, Pauleen MT, Ljungman EA, Bedi K, Prasad J, Wilson TE, Ljungman M. Identifying transcription start sites and active enhancer elements using BrulUV-seq. Sci Rep. 2015;5:17978.
26. Hu J, Adar S, Selby CP, Lieb JD, Sancar A. Genome-wide analysis of human global and transcription-coupled repair of UV damage at single-nucleotide resolution. Genes Dev. 2015;29:948–60.
27. Onzunzain, S. Pedrazzini T. Super-enhancer Incs to cardiovascular development and disease. Biochim Biophys Acta. 1863;2016:1953–60.
28. Xiang JF, Yin QF, Chen T, Zhang Y, Zhang XD, Wu Z, Zhang S, Wang HB, Ge J, Lu X, et al. Human colorectal cancer-specific CCAT1-L InRna regulates long-range chromatin interactions at the MYC locus. Cell Res. 2014;24:513–31.
29. Onzunzain, S. Micheleetti R, Aman C, Plaisance I, Cecchi D, Schroen B, Reverter F, Alexanian M, Gonzales C, Ng ST, et al. CARMEN, a human super enhancer-associated long noncoding RNA controlling cardiac specification, differentiation and homeostasis. J Mol Cell Cardiol. 2013;59:989–112.
30. Niedenfert AR, Varshney A, Parker SC, Martin DM. Super enhancers in cancers, complex disease, and developmental disorders. Genes (Basel). 2015;6:1189–200.
31. Luo Z, Lin C. Enhancer, epigenetics, and human disease. Curr Opin Genet Dev. 2016;36:227–33.
44. Su ZD, Huang Y, Zhang ZY, Zhao YW, Wang D, Chen W, Chou KC, Lin H. lncRNA predict the subcellular location of IncRNAs by incorporating octamer composition into general PseKNC. Bioinformatics. 2018;34:1196–204.
45. Ciechewicz MA, Kitan M, Przanowska RK, Sobierajaska E, Shibata Y, Dutta A. MUNC, an enhancer RNA upstream from the MYC2 gene, induces a subgroup of myogenic transcripts in trans independently of MyoD. Mol Cell Biol. 2018;38:e00655–17.
46. Struhl K. Transcriptional noise and the fidelity of initiation by RNA polymerase II. Nat Struct Mol Biol. 2007;14:103–5.
47. Zhang Z, Lee JH, Ruan H, Ye Y, Krakowkaj H, Hu Q, Xiang Y, Gong J, Zhou B, Wang L, et al. Transcriptional landscape and clinical utility of enhancer RNAs for RNA-targeted therapy in cancer. Nat Commun. 2019;10:4562.
48. Buxfey AD, Mendes CC, McGregor AP. The functionality and evolution of eukaryotic transcriptional enhancers. Adv Genet. 2016;96:143–206.
49. Fan J, Xu Y, Wen G, Ge S, Jia R, Zhang H, Fan XA. Cohesin-mediated Intrachromosomal loop drives oncogenic ROR IncRNA to accelerate tumorigenesis. Mol Ther. 2019;27:2182–94.
50. Li N, Notani D, Ma Q, Tanasa B, Nunez E, Chen AY, Merukjev D, Zhang J, Ohtgi K, Song X, et al. Functional roles of enhancer RNAs for oestrogen-dependent transcriptional activation. Nature. 2013;498:16–20.
51. Levelle E, Melo CA, Agami R. Enhancer-associated RNAs as therapeutic targets. Expert Opin Biol Ther. 2015;15:723–34.
52. Oldridge DA, Wood AC, Weichert-Leahey N, Crimmins I, Sussman R, Winter Leveille N, Melo CA, Agami R. Enhancer-associated RNAs as therapeutic agents. Adv Genet. 2016;96:143–206.
53. Kandaswamy R, Sava GP, Speedy HE, Bea S, Martin-Subero JI, Studd JB, Oldridge DA, Wood AC, Weichert-Leahey N, Crimmins I, Sussman R, Winter Leveille N, Melo CA, Agami R. Enhancer-associated RNAs as therapeutic agents. Adv Genet. 2016;96:143–206.
85. Witte S, O'Shea JJ, Vahedi G. Super-enhancers: Asset management in immune cell genomes. Trends Immunol. 2015;36:519–26.
86. Kitagawa Y, Okhura N, Kidani Y, Vandebroek A, Hirota K, Kawakami R, Yasuda K, Motoo D, Nakamura S, Kondo M, et al. Guidance of regulatory T cell development by Sbf1-dependent super-enhancer establishment. Nat Immunol. 2017;18:173–83.
87. Le Noir S, Boyer F, Lecadreur S, Brousse M, Oruc Z, Cook-Moreau J, Denizot Y, Cogne M. Functional anatomy of the immunoglobulin heavy chain 3 super-enhancer needs not only core enhancer elements but also their unique DNA context. Nucleic Acids Res. 2017;45:5828–37.
88. Agirre X, Meydan J, Yang J, Garate L, Doane AS, Li V, Verma A, Paiva B, Martin-Saberlo J, Elemento O, et al. Long non-coding RNAs discriminate the stages and gene regulatory states of human humoral immune response. Nat Commun. 2019;10:821.
89. Teppo S, Laukkanen S, Liukisala T, Nordlund M, Tottinen M, Teittinen K, Gronroos T, St-Onge P, Sippett D, Syvanen AC, et al. Genome-wide repression of eRNA and target gene loss by the ETV6-RUNX1 fusion in acute leukemia. Genome Res. 2016;26:1468–77.
90. Han H, Benner C, Chong LW, Yu RT, Downes M, Evans RM. Inflammation-sensitive super enhancers form domains of coordinately regulated enhancer RNAs. Proc Natl Acad Sci U S A. 2015;112:2907–2912.
91. Gibbons HR, Mi DJ, Farley VM, Esmond T, Kaood MB, Aune TM. Bromodomain inhibitor JQ1 reversibly blocks IFN-gamma production. Sci Rep. 2016;6:27505.
92. Ozawa T. In situ characterization of Bak clusters responsible for cell death via activation of the Mechanosensitive YAP/TAZ transcriptional pathway in cancer. Cell Death Differ. 2018;25:1261–71.
93. Hsu YC, Chang GR, Pan JY, Rajandran P, Mathew DC, Li ML, Liao JW, Chen WT, Yang HL. Antitumor camptothecin inhibits epithelial-to-mesenchymal transition by targeting multiple pathways in triple-negative breast cancers. J Cell Physiol. 2019;234:4125–39.
94. Valllard C, Larriue B. Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Anzioinogenes. 2017;20:499–26.
95. Dui J, Wei P, Zhang P, Kong B. Overexpression of microRNA-195-5p reduces cisplatin resistance and angiogenesis in ovarian cancer by inhibiting the PSAT1-dependent GSK3beta/beta-catenin signaling pathway. J Transl Med. 2019;17:190.
96. Yuan Z, Bian Y, Ma X, Tang Z, Chen N, Shen M. LncRNA H19 knockdown in human anaplastic Mesenchymal stem cells suppresses angiogenesis by associating with E2F4 and activating Vash1. Stem Cells Dev. 2019;28:781–90.
97. Spurlock CF 3rd, Shagnuruvosa G, Tossberg JT, Hester JD, Chapman N, Guo Y, Crooke PS 3rd, Aune TM. Profiles of Long noncoding RNAs in human naive and memory T cells. J Immunol. 2017;199:547–58.
98. Wu M, Shen J. From super-enhancer non-coding RNA to immune checkpoint: workflows to functions. Front Oncol. 2019;9:1307.
99. Garcia-Diaz A, Shin DS, Moreno BH, Saccu J, Escuin-Ordinas H, Rodriguez GA, Zankovsky JM, Sun L, Hugo W, Wang X, et al. Interleukin receptor signaling pathways regulating PD-1L and PD-L2 expression. Cell Rep. 2017;19:1189–201.
100. Zhou B, Cheng SC, Freitas VM. Extracellular matrix influencing HGF/c-MET signaling pathway: impact on Cancer progression. J Cell Biochem. 2017;164:257–64.
101. Noriega-Guerra H, Spurlock CF 3rd, Martin BP, Spencer A, et al. BET-bromodomain inhibitors engage the host immune system and regulate expression of the immune checkpoint ligand PD-L1. Cell Rep. 2017;18:2162–74.
102. Noriega-Guerra H, Freitas VM. Extracellular matrix influencing HGF/c-MET signaling pathway: impact on Cancer progression. J Cell Biochem. 2018;164:257–64.
103. Martin BP, Spencer A, et al. BET-bromodomain inhibitors engage the host immune system and regulate expression of the immune checkpoint ligand PD-L1. Cell Rep. 2017;18:2162–74.
104. Matsumoto K, Takamura K, Takahara K, et al. Induction of PD-L1 expression by the EML4-ALK Oncoprotein and downstream signaling pathways in non-small cell lung cancer. J Clin Cancer Res. 2015;21:4014–21.
105. Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, Gouw AM, Baylot V, Gutgemann I, Eilers M, Felsher DW. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016;352:227–32.
106. Tsang FH, Law CT, Tang TC, Cheng CL, Chin DW, Lo TK, Tam WV, Wei L, Wong CC, et al. Molecular Cancer 2020;19:74.
130. Giussani M, Merlino G, Cappelletti V, Tagliabue E, Daidone MG. Tumor-extracellular matrix interactions: identification of tools associated with breast cancer progression. Semin Cancer Biol. 2015;35:3–10.

131. Hirata E, Grozity MR, Viros A, Hooper S, Spencer-Dene B, Matsuda M, Larkin J, Marais R, Sahai E. Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin beta1/FAK signaling. Cancer Cell. 2015;27:574–88.

132. Yoshida GJ. Applications of patient-derived tumor xenograft models and tumor organoids. J Hematol Oncol. 2020;13:4.

133. Yoo KH, Hennighausen L, Shin HY. Dissecting tissue-specific super-enhancers by integrating genome-wide analyses and CRISPR/Cas9 genome editing. J Mammary Gland Biol Neoplasia. 2019;24:47–59.

134. Pefanis E, Wang J, Rothchild G, Lim J, Kazadi D, Sun J, Federation A, Chao J, Elliott O, Liu ZP, et al. RNA exosome-regulated long non-coding RNA transcription controls super-enhancer activity. Cell. 2015;161:774–89.

135. Thandapani P. Super-enhancers in cancer. Pharmacol Ther. 2019;199:129–38.

136. Zhou H, Schmidt SC, Jiang S, Willox B, Bernhardt K, Liang J, Johannsen EC, Kharchenko P, Gewurz BE, Kieff E, Zhao B. Epstein-Barr virus oncprotein super-enhancers control B cell growth. Cell Host Microbe. 2015;17:205–16.

137. Eliades P, Abraham BJ, Ji Z, Miller DM, Christensen CL, Kwiatkowski N, Kumar R, Njauw CN, Taylor M, Miao B, et al. High MITF expression is associated with super-enhancers and suppressed by CDK7 inhibition in melanoma. J Invest Dermatol. 2018;138:1582–90.

138. Pelish HE, Liau BB, Nitulescu II, Tangpeerasakul A, Poss ZC, Da Silva DH, Caruso BT, Arefolov A, Christie AL, et al. Mediator kinase inhibition further activates super-enhancer-associated genes in AML. Nature. 2015;526:273–6.

139. Geng M, Yang Y, Cao X, Dang L, Zhang T, Zhang L. Targeting CDK12-mediated transcription regulation in anaplastic thyroid carcinoma. Biochem Biophys Res Commun. 2019;520:544–5049.

140. Kennedy AL, Vaililupali M, Chen L, Crompton B, Cowley G, Vazquez F, Weir BA, Therniak A, Paraturaman S, Kim S, et al. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma. Oncotarget. 2015;6:30178–93.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.